公开(公告)号：US08623358B2

公开(公告)日：2014-01-07

申请号：US12870276

申请日：2010-08-27

申请人： Lorenzo Benatuil ,  Erwin R. Boghaert ,  Jijie Gu ,  Maria Harris ,  Jonathan A. Hickson ,  Chung-Ming Hsieh ,  Yuliya Kutskova ,  Yingchun Li ,  Zhihong Liu ,  Susan Morgan-Lappe

发明人： Lorenzo Benatuil ,  Erwin R. Boghaert ,  Jijie Gu ,  Maria Harris ,  Jonathan A. Hickson ,  Chung-Ming Hsieh ,  Yuliya Kutskova ,  Yingchun Li ,  Zhihong Liu ,  Susan Morgan-Lappe

IPC分类号： A61K39/395

CPC分类号： C07K16/22 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  C07K7/06 ,  C07K7/08 ,  C07K14/47 ,  C07K16/18 ,  C07K2317/21 ,  C07K2317/33 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2317/94

摘要： Improved DLL4 binding proteins are described, including antibodies, CDR-grafted antibodies, human antibodies, and DLL4 binding fragments thereof, proteins that bind DLL4 with high affinity, and DLL4 binding proteins that neutralize DLL4 activity. The DLL4 binding proteins are useful for treating or preventing cancers and tumors and especially for treating or preventing tumor angiogenesis, and/or other angiogenesis-dependent diseases such as ocular neovascularization, or angiogenesis-independent diseases characterized by aberrant DLL4 expression or activity such as autoimmune disorders including multiple sclerosis.

摘要翻译： 描述了改进的DLL4结合蛋白，包括抗体，CDR-移植抗体，人抗体和DLL4结合片段，以高亲和力结合DLL4的蛋白质，以及中和DLL4活性的DLL4结合蛋白。 DLL4结合蛋白可用于治疗或预防癌症和肿瘤，特别是用于治疗或预防肿瘤血管生成和/或其它血管发生依赖性疾病，例如眼新生血管形成或以异常DLL4表达或活性为特征的血管发生非依赖性疾病，例如自身免疫 包括多发性硬化的疾病。

公开(公告)号：US20110117079A1

公开(公告)日：2011-05-19

申请号：US12870276

申请日：2010-08-27

申请人： Lorenzo Benatuil ,  Erwin R. Boghaert ,  Jijie Gu ,  Maria Harris ,  Jonathan A. Hickson ,  Chung-Ming Hsieh ,  Yuliya Kutskova ,  Yingchun Li ,  Zhihong Liu ,  Susan Morgan-Lappe

发明人： Lorenzo Benatuil ,  Erwin R. Boghaert ,  Jijie Gu ,  Maria Harris ,  Jonathan A. Hickson ,  Chung-Ming Hsieh ,  Yuliya Kutskova ,  Yingchun Li ,  Zhihong Liu ,  Susan Morgan-Lappe

IPC分类号： A61K39/395 ,  C07K16/18 ,  C12N9/96 ,  C07H21/04 ,  C12N15/63 ,  C12N1/21 ,  C12N5/10 ,  C12N1/19 ,  C12P21/00 ,  A61P35/00 ,  A61P13/08 ,  A61P9/10 ,  A61P17/02 ,  A61P35/04

CPC分类号： C07K16/22 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  C07K7/06 ,  C07K7/08 ,  C07K14/47 ,  C07K16/18 ,  C07K2317/21 ,  C07K2317/33 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2317/94

摘要： Improved DLL4 binding proteins are described, including antibodies, CDR-grafted antibodies, human antibodies, and DLL4 binding fragments thereof, proteins that bind DLL4 with high affinity, and DLL4 binding proteins that neutralize DLL4 activity. The DLL4 binding proteins are useful for treating or preventing cancers and tumors and especially for treating or preventing tumor angiogenesis, and/or other angiogenesis-dependent diseases such as ocular neovascularization, or angiogenesis-independent diseases characterized by aberrant DLL4 expression or activity such as autoimmune disorders including multiple sclerosis.

摘要翻译： 描述了改进的DLL4结合蛋白，包括抗体，CDR-移植抗体，人抗体和DLL4结合片段，以高亲和力结合DLL4的蛋白质，以及中和DLL4活性的DLL4结合蛋白。 DLL4结合蛋白可用于治疗或预防癌症和肿瘤，特别是用于治疗或预防肿瘤血管生成和/或其它血管发生依赖性疾病，例如眼新生血管形成或以异常DLL4表达或活性为特征的血管发生非依赖性疾病，例如自身免疫 包括多发性硬化的疾病。